Clinical trials of Shigella vaccines in Israel

Advances in Experimental Medicine and Biology

Volumn 397, Issue , 1996, Pages 159-167

  Cohen, D ^a   Ashkenazi, S ^a   Green, M ^a   Gdalevich, M ^a   Yavzori, M ^a   Orr, N ^a   Robin, G ^a   Slepon, R ^a   Lerman, Y ^a   Block, C ^a   Ashkenazi, I ^a   Taylor, D ^b   Hale, L ^b   Sadoff, J ^b   Schneerson, R ^c   Robbins, J ^c   Wiener, M ^a   Shemer, J ^a  

^a Medical Corps   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SHIGELLA VACCINE;

ANTIGEN PRESENTATION; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CONFERENCE PAPER; DRUG EFFICACY; IMMUNOGENICITY; ISRAEL; NONHUMAN; PRIORITY JOURNAL; SAFETY; SHIGELLOSIS; VACCINATION;

EID: 9044225141     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4899-1382-1_21     Document Type: Conference Paper

References (27)

1. Ashkenazi S., May-Zahav M., Dinari G., Gabbay U., Zilberman A., and Samra Z. 1993. Recent trends in the epidemiology of Shigella infections. Clin. Infect. Dis. 17:897-899.
2. Chu C. Y., Liu B., Watson D., Szu S. C., Bryla D., Shiloach J., Schneerson R., and Robbins J. 1992. Preparation, characterization and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect. Immun. 59:4450-4458.
3. Cohen D., Green M. S., Block C., Rouach T., and Ofek I. 1988. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J. Infect. Dis. 157:1068-1071.
4. Cohen D., Green M., Block C., Lowell G., and Ofek I. 1989. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J. Clin. Microbiol. 27:162-167.
5. Cohen D., Green M., Block C., Slepon R., Ambar R., Wasserman S, and Levine M. M. 1991. Reduction of transmission of shigellosis by control of house flies (Musca domestica). Lancet 337:993-997.
6. Cohen D., Ashkenazi S., Green M. S., Yavzori M., Orr N., Slepon R., Lerman Y., Robin G., Ambar R., Block C., Taylor D. N., Hale T. L., Sadoff J. C., and Wiener M. 1994. Safety and immunogenicity of the oral E. coli K12-S. flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers. Vaccine 12:1436-1442.
7. DuPont H. L., Levine M. M., Hornick R. B., and Formal S. B. 1989. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159:1126-1128.
8. Formal S. B., Hale T. L., Kapfer C., Cogan J. P., Snoy P. J., Chung Y., Wingfield M. E., Elisberg B. L., and Baron L. S. 1984. Oral vaccination of monkeys with an invasive Escherichia coli K12 hybrid expressing Shigella flexneri 2a somatic antigen. Infect. Immun. 46:465-469.
9. Green M. S., Cohen D., Block C., Rouach T., and Dycian R. 1987. A prospective epidemiologic study of shigellosis. Implications for the new Shigella vaccines. Isr. J. Med. Sci. 23:811-815.
10. Green M. S., Block C., Cohen D., and Slater P. 1991. Four decades of shigellosis in Israel - the epidemiology of a growing public health problem. Rev. Inf. Dis. 13:248-253.
11. Herrington D. A., Van De Verg L., Formal S. B., Hale T. L., Tall B. D., Cryz S. J., Tramont E. C., and Levine M. M. 1990. Studies in volunteers to evaluate candidate Shigella vaccines. Further experience with a bivalent Salmonella tvphi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8:353-357.
12. Institute of Medicine. Prospects for immunizing against Shigella spp. In: New Vaccine Development: Establishing Priorities: Diseases of Importance in Developing Countries, vol. 2; National Academic Press. Washington, D.C., 1986:329-337.
13. Kotloff L. K., Herrington D. A., Hale T. L., Newland J. W., Van De Verg L., Cogan J. P., Snoy P. J., Sadoff J. C., Formal S. B., and Levine M. M. 1992. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect. Immun. 60:2218-2224.
14. Levine M. M., DuPont H. L., Gangarosa E. J., Hornick R. B., Snyder M. J., Libonati J. P., Glaser K., and Formal S. B. 1972. Shigellosis in custodial institutions. II. Clinical immunologic and bacteriologic response of institutionalized children to oral attenuated Shigella vaccines. Am. J. Epidemiol. 966:40-49.
15. Li A., Karnell A., Huan P. T., Cam P. D., Minh N. B., Tram L. N., et al. 1993. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers. Vaccine 11:180-189.
16. Lindberg A. A., Karnell A., and Stocker B.A.D. Aromatic-dependent Shigella strains as oral live vaccines. In: Woodrow G. C., Levine M. M. (eds.), New Generation Vaccines. Vaccines against Shigella part II. Marcel Dekker, New York, 1990:677-687.
17. Ncwland J. W., Hale T. L., and Formal S. B. 1992. Genotypic and phenotypic characterization of an aroD deletion attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen. Vaccine 10:766-776.
18. Noriega F. R., Wang J. Y., Losonsky G., Maneval D. R., Hone D. M., and Levine M. M. 1994. Construction and characterization of attenuated ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect. Immun. 62:5168-5172.
19. Orr N., Robin G., Lowell G., and Cohen D. 1992. Presence of specific immunoglobulin A secreting cells in peripheral blood following natural infection with Shigella sonnei. J. Clin. Microbiol. 30:2165-2168.
20. Orr N., Robin G., Cohen D., Arnon R., and Lowell G. H. 1993. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. 61:2390-2395.
21. Robbins J. B., Chu C. Y., and Schneerson R. 1992. Hypothesis for vaccine development: serum IgG LPS antibodies confer protective immunity to non-typhoidal Salmonellae and Shigellae. Clin. Infect. Dis. 15:346-361.
22. Sanchez J. L., Trofa A. F., Taylor D. N., Kushner R. A., DeFraites R. F., Craig S. C., Rao M. R., Clemens J. D., Svennerholm A., Sadoff J. C., and Holmgren J. 1993. Safety and immunogenicity of the oral. whole cell recombinant B subunit cholera vaccine in North American volunteers. J. Infect. Dis. 167:1446-1449.
23. Sansonnelti P. J. and Arondel J. 1989. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 7:443-450.
24. Smollan G. and Block C. 1992. Development of antimicrobial drug resistance among Shigellas isolated at an Israeli hospital from 1977 through 1990. Publ. Health Rev. 18:319-327.
25. Taylor D. N., Trofa A. C., Sadoff J., Chu C. Y., Bryla D. A., Shiloach J., Cohen D., Ashkenazi S., Lerman Y., Egan M., Schneerson R., and Robbins J. 1993. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1. Shigella flexneri type 2, Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun. 61:3678-3687.
26. Taylor D., Phillip D. F., Zapor M., Trofa A., Van de Verg L., Hartman A., Bendiuk N., Newland J. W., Formal S. B., and Sadoff J. C. 1994. Outpatient studies of the safety and immunogenicity of the auxotrophic Escherichia coli-Shigella flexneri hybrid vaccine candidate EcSf2a-2. Vaccine 12:565-568.
27. Tramont E. C., Chung R., Berman S., Keren D., Kapfer C., and Formal S. B. 1984. Safety and antigenicity of Typhoid-Shigella sonnei vaccine (Strain 5076-IC). J. Infect. Dis. 149:133-136.